Farrow Jeffrey S 4
4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 20, 2024
Insider Transaction Report
Form 4
Farrow Jeffrey S
See Remarks
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-06-17−27,881→ 83,644 total→ Common Stock (27,881 underlying) - Sale
Common Stock
2024-06-18$27.47/sh−10,445$286,924→ 18,136 total - Exercise/Conversion
Common Stock
2024-06-17+27,881→ 28,581 total
Footnotes (4)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F4]RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.